IgA nephritis: ACE inhibitors, steroids, both or neither?

Nephrology Dialysis Transplantation

Volumn 21, Issue 12, 2006, Pages 3357-3361

  Locatelli, Francesco ^a   Pozzi, Claudio ^a   Andrulli, Simeone ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

ACE inhibitors; Angiotensin II receptor blockers; Cytotoxic drugs; IgA Nephritis; Renal progression; Steroids; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIOXIDANT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PREDNISONE; STEROID; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN DEPOSITION; INCIDENCE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STEROID THERAPY; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 33751419293     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl508     Document Type: Note

References (38)

1. Locatelli F, Del Vecchio L, Pozzi C. IgA glomerulonephritis: Beyond angiotensin-converting enzyme inhibitors. Nat Clin Prac Nephrol 2006; 2: 26-31
2. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 2006; 69: 1939-1944
3. Appel GB. To treat or not to treat IgA nephropathy? Clin J Am Soc Nephrol 2006; 1: 347-348
4. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 265-269
5. Woo KT, Lau YK, Wong KS, Chiang GSC. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000; 58: 2485-2491
6. Russo D, Minutolo R, Pisani A et al. Coadministration of Losartan and Enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25
7. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117-124
8. Praga M, Gutierrez E, Gonzales E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
9. Horita Y, Tadokoro M, Taura K et al. Low-dose combination therapy with Temocapril and Losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 2004; 27: 963-970
10. Li PK, Leung CB, Chow KM et al. HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47: 751-760
11. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49: 578-597
12. Hale GM, Howarth GS, Aarons I, Clarkson AR, Woodroffe AJ. Quantitation of glomerular angiotensin II receptors in IgA nephropathy. Clin Nephrol 1989; 32: 5-9
13. Coppo R, Amore A, Gianoglio B et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993; 21: 593-602
14. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA with nephritic syndrome: A long-term controlled trial. Clin Nephrol 1986; 26: 174-180
15. Welch TR, Fryer C, Shely E, Witte D, Quinian M. Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Ped 1992; 121: 471-477
16. Julian BA, Baker C. Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol 1993; 104: 198-206
17. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. Nephron 1996; 72: 237-242
18. Shoji T, Nakanishi I, Suzuki A et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 2000; 35: 194-201
19. Katafuchi R, Ikeda K, Mizumasa T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41: 972-983
20. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353: 883-887
21. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropatby: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163
22. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - New mechanisms for old drugs. New Engl J Med 2005; 353: 1711-23
23. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators: effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
24. Lewis EJ, Hunsicker LG, Clarke WR et al. For the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
25. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
26. Samuels JA, Strippoli GF, Craig JC et al. Immunosuppressive treatments for immunoglobulin A nephropathy: A meta-analysis of randomized controlled trials. Nephrology 2004; 9: 177-185
27. Hogg RJ, Lee J, Nardelli N et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: Report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1: 467-474
28. Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
29. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849
30. Tang S, Leung JC, Chan LY et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-12
31. Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-2145
32. Locatelli F, Pozzi C, Del Vecchio L et al. Combined treatment with steroids and azathioprine in IgA nephropathy: Design of a prospective randomised multicentre trial. J Nephrol 1999; 12: 308-311
33. Yoshikawa N, Honda M, Iijima K et al. for the Japanese Pediatric IgA Nephropathy Treatment Study Group. Steroid treatment for severe childhood IgA nephropathy: A randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1: 511-517
34. Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110: 434-437
35. Usui J, Yagamata K, Kai H et al. Heterogeneity of prognosis in Adult IgA Nephropathy, especially with mild proteinuria on mild histological features. Intern Med 2001; 40: 697-702
36. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-512
37. Deschamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Early prediction of IgA nephropathy progression: Proteinuria and AOOP are strong prognostic markers. Kidney Int 2004; 66: 1606-12
38. Pozzi C, Del Vecchio L, Casartelli D et al. ACE-inhibitors and angiotensin-II receptor blockers in IgA nephropathy with mild proteinuria: The ACEARB study. J Nephrol 2006; (in press)